Roche’s Kadcyla Delayed In Japan And Simeprevir Gets First Market Nod In New Chuikyo Price Listings
This article was originally published in PharmAsia News
Executive Summary
Japan subsidiary Chugai will launch clinical trials in January to provide patients access to Kadcyla while the company renegotiates the reimbursement price for the antibody drug conjugate.